Interferons and bladder cancer (Q33851158)

29 July 2017

1 reference

title

Interferons and bladder cancer (English)

1 reference

29 July 2017

Brown DH

1

1 reference

29 July 2017

Wagner TT

series ordinal

2

1 reference

29 July 2017

Bahnson RR

series ordinal

3

1 reference

29 July 2017

1 February 2000

1 reference

Urologic Clinics of North America

29 July 2017

1 reference

29 July 2017

27

1 reference

29 July 2017

171-8, xi

1 reference

29 July 2017

1

1 reference

Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Antiproliferative Activities of Interferons Against Human Bladder Carcinoma Cell Lines in Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Enhancement of natural cytotoxicity in lymphocytes from animals with carcinogen-induced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Intravesical instillation of beta-interferon in the treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A,B,C and DR in human urothelial cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Role of fibronectin in intravesical BCG therapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970245-7

7 January 2021

10.1016/S0094-0143(05)70245-7

Identifiers

DOI

1 reference

release_wkg52nebzngrzof4yb3uqmtbgi

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wkg52nebzngrzof4yb3uqmtbgi

24 November 2022

mapped directly with Wikidata item

1 reference